Tradestie Institutional Equity Comparison Engine

CLYM vs PLUR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while PLUR counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PLUR at 3.6x Forward P/E and -2454.5% operating margin (-15.8% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PLUR
CLYM N/M vs PLUR 3.6x Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs -2454.5% ยท YoY +0.0% vs -15.8%
Momentum & Technical Winner CLYM
1Y +407.4% vs -78.8% ยท 52W Pos 48% vs 2%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap $608.5M
1M Return -0.92%
1Y Return +407.37%
Forward P/E N/M
Unified AI Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
1M Return +11.09%
1Y Return -78.78%
Forward P/E 3.6x
Unified AI Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +407.37% PLUR -78.78% Spread: +482.9 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% PLUR TTM Op. Margin: -2454.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs PLUR. Trailing 12-month operating profitability (CLYM 0.0% vs PLUR -2454.5%) and valuation multiples (CLYM N/M vs PLUR 3.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (6) vs PLUR (3)
Institutional Metric CLYM PLUR Criterion Row Winner
Market Capitalization Scale $608.5M $15.1M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M 3.6x Lower Multiple PLUR
Forward P/E Ratio Valuation N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY) Growth +0.0% -15.8% Higher Growth CLYM
Operating Margin (TTM) Profitability 0.0% -2454.5% Higher Margin CLYM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -1022.0% Higher ROE CLYM
52-Week Range Position Momentum 48% ($2โ€“$18) 2% ($1โ€“$5) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 112% Vol 0.80ฮฒ ยท 102% Vol Lower Realized Risk PLUR
Unified Institutional Score Composite Signal 45.7 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs PLUR Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PLUR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor PLUR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.